SODIUM PHOSPHATES IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SODIUM PHOSPHATES IN PLASTIC CONTAINER (SODIUM PHOSPHATES IN PLASTIC CONTAINER).
Sodium phosphates increase serum phosphate concentration, promoting renal excretion of calcium and phosphate, and inducing osmotic diarrhea to cleanse the colon.
| Metabolism | Not metabolized; renally excreted. |
| Excretion | Primarily renal (≥90% as inorganic phosphate and sodium). Fecal elimination is minimal (<5%) via unabsorbed phosphate. |
| Half-life | Terminal half-life of absorbed phosphate is approximately 0.5–1 hour in patients with normal renal function. Clinically, effects on serum phosphate are transient and depend on renal clearance. |
| Protein binding | Negligible (<1%); phosphate exists primarily as free anion. |
| Volume of Distribution | Approximately 0.2–0.3 L/kg, reflecting distribution primarily in extracellular fluid; does not extensively penetrate cells. |
| Bioavailability | Oral: approximately 30–50% (variable due to incomplete absorption and first-pass renal excretion). |
| Onset of Action | Oral: cathartic effect within 0.5–6 hours; intravenous: serum phosphate increase within minutes. |
| Duration of Action | Oral: catharsis lasting 1–3 hours. Intravenous: serum phosphate elevation lasts 1–2 hours post-infusion due to rapid renal elimination. |
Oral: 30-90 mL (equivalent to 3.75-11.25 g sodium phosphate) once daily, preferably in the morning, with a full glass of water. Dose may be increased up to 240 mL per day in divided doses. Rectal enema: 118 mL (monobasic sodium phosphate 19 g, dibasic sodium phosphate 7 g) as a single dose.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated in patients with GFR < 30 mL/min/1.73 m2. For GFR 30-59 mL/min/1.73 m2, use with caution and reduce dose by 50%; monitor serum phosphate and electrolytes. Avoid in severe renal impairment. |
| Liver impairment | No specific dose adjustment for Child-Pugh class A, B, or C. Caution in ascites due to potential fluid shifts. Use lowest effective dose. |
| Pediatric use | Oral: For constipation, 2.5-10 mL (0.3-1.25 g) once daily for children 2-5 years; 10-20 mL (1.25-2.5 g) for 6-12 years; 20-40 mL (2.5-5 g) for 12 years and older. Rectal enema: 33-66 mL for children 5-11 years; 118 mL for ≥12 years. Dosing based on weight: 0.5-1 mL/kg per dose for oral solution, max 240 mL/day. |
| Geriatric use | Start at lower end of dosing range (30 mL oral once daily). Monitor renal function, electrolytes, and fluid balance. Avoid in elderly with reduced GFR. Increased risk of hyperphosphatemia and dehydration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SODIUM PHOSPHATES IN PLASTIC CONTAINER (SODIUM PHOSPHATES IN PLASTIC CONTAINER).
| Breastfeeding | Limited data; phosphate is a normal component of breast milk. M/P ratio not established. Intravenous or oral sodium phosphates are not expected to cause harm to breastfeeding infant when given at therapeutic doses. However, caution with high doses due to potential for maternal electrolyte imbalance affecting milk composition. Use only if clearly needed. |
| Teratogenic Risk | Sodium phosphates are not associated with teratogenicity in animal studies. However, electrolyte imbalances (hypernatremia, hyperphosphatemia) secondary to excessive dosing could potentially affect fetal development indirectly. In the first trimester, avoid high doses due to theoretical risk of electrolyte disturbance affecting organogenesis. In second and third trimesters, use only if clearly needed and with monitoring of maternal electrolytes to prevent fetal acidosis or dehydration. |
■ FDA Black Box Warning
Risk of acute phosphate nephropathy, including permanent renal impairment and need for dialysis, especially in patients with impaired renal function, dehydration, or those taking medications that affect renal function.
| Serious Effects |
Renal impairment (e.g., GFR < 30 mL/min), bowel obstruction, perforation, congenital megacolon, ascites, severe dehydration, hypersensitivity to sodium phosphates.
| Precautions | Avoid in patients with renal impairment, bowel obstruction, colitis, or dehydration; monitor electrolytes; risk of seizures due to electrolyte disturbances. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes (sodium, phosphate, calcium, potassium), renal function, and acid-base status. In prolonged use or high doses, consider fetal heart rate monitoring and ultrasound for signs of fetal hydrops or electrolyte disturbances. Monitor for maternal signs of hypernatremia or hypocalcemia. |
| Fertility Effects | No known adverse effects on fertility in animal studies. High doses causing severe electrolyte disturbances could theoretically impair reproductive function, but at therapeutic doses no impact is expected. |